From Seattle, at the 9th Annual Conference on Retroviruses and Opportunistic Infections
Three potential drugs in development rely on novel tactics for attacking HIV, the virus that causes AIDS.
A compound dubbed BMS-806 blocks the entry of HIV into cells, reports Richard J. Colonno of Bristol-Myers Squibb in Wallingford, Conn. In test tubes, the compound inhibits the replication of HIV, including strains already resistant to other drugs.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.